An In-Depth Overview of Interstitial Lung Diseases for Healthcare Professionals
OthersPage Navigation
Introduction
Interstitial Lung Diseases (ILDs) encompass over 200 pulmonary disorders, characterized by fibrotic and inflammatory changes in the lung interstitium.
Etiology and Classification
ILDs can be idiopathic, or related to systemic diseases, environmental exposure, or drugs. They're classified into four categories: idiopathic interstitial pneumonias, ILDs associated with systemic diseases, granulomatous ILDs, and other ILDs.
Clinical Presentation and Diagnosis
Patients typically present with dyspnea and dry cough. Diagnosis involves clinical evaluation, pulmonary function tests, high-resolution CT, and sometimes lung biopsy.
Treatment
Treatment varies depending on the specific ILD and its cause, but often involves corticosteroids and immunosuppressants.
Conclusion
Understanding ILDs is crucial for early detection and appropriate treatment, thereby improving patient outcomes.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Radiation from CT scans could account for 5% of all cancer cases a year, study suggests
3.
Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer
4.
In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.
5.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
1.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
2.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
3.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
4.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
5.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge